9/10/2013

Biogen Idec signed a deal with Isis Pharmaceuticals to develop new treatments for neurological diseases using the latter's antisense technology. The current deal, which entitles Isis to $100 million upfront, is the fourth collaboration between the firms in the past two years. Isis will get milestone and licensing fees plus sales royalties on products arising from the collaboration.

Related Summaries